Recent Updates
Recently added Catalysts

Pacibekitug

Phase 3

Myocardial Infarction | Biologics | Other |Novartis AG|Trials Updated: Nov 16, 2026

Pacibekitug development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Nov 2026

Pacibekitug target and mechanism

ModalityBiologics

Also known as PAC001, TOUR006

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment10,000

FDA Designations

No designations recorded

Pacibekitug clinical trials

Pacibekitug · 1 trial · 1 indication

Phase 3 1
NCT07938411A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial InfarctionMyocardial Infarction
NOT YET_RECRUITING10,000 Analytics
PHASE3NOT YET_RECRUITING
A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
Myocardial InfarctionUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to the first occurrence of 3P-Coronary-MACE
Up tp 1398 days

3-point Coronary major adverse cardiovascular events (3P-Coronary-MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization

Secondary Endpoints

Time to the first occurrence of 4P-MACE
Up tp 1398 days
Time to the first occurrence of 3P-MACE
Up tp 1398 days
Time to the first occurrence of 4P-MACE or MALE
Up tp 1398 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PacibekitugEXPERIMENTALpacibekitug s.c.
PlaceboPLACEBO_COMPARATORPlacebo s.c.

Interventions

NameTypeDescription
PacibekitugDRUGpacibekitug s.c.
PlaceboDRUGPlacebo s.c.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: The key inclusion criteria are as follows: * Adults aged ≥ 18 years at the time of informed consent form (ICF) signature. * Diagnosis of spontaneous (type 1) MI based on medical records and the Investigator's judgment. Patients must be either: 1. ≤ 30 days from the index MI ...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 16, 2026NCT07938411NEW_TRIAL: changed
LOWNov 16, 2026NCT07938411NEW_TRIAL: changed

Frequently asked questions about Pacibekitug

What is pacibekitug?

Pacibekitug is an investigational biologic drug being developed by Novartis AG for patients who have had a myocardial infarction, commonly called a heart attack. It is in Phase 3 clinical development and is designed to be studied for its effect on major cardiovascular events after a myocardial infarction.

What is pacibekitug used for?

Pacibekitug is being developed for use in patients after a myocardial infarction, with the goal of assessing its effect on major cardiovascular events. It is investigational and is being studied in a Phase 3 trial; it is not yet established as a treatment for this population.

Who makes pacibekitug?

Pacibekitug is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the Phase 3 program evaluating pacibekitug in patients following a myocardial infarction.

What phase is pacibekitug in?

Pacibekitug is in Phase 3 clinical development. It is an investigational biologic and is not approved; the Phase 3 program is evaluating its effect on major cardiovascular events in patients after a myocardial infarction.

What clinical trials is pacibekitug in?

Pacibekitug is being studied in the Phase 3 trial NCT07938411, titled A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction. The trial is not yet recruiting, plans to enroll 10,000 participants aged 18 years and older of all sexes, and is randomized, double-blind, and placebo-controlled.